Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Tocagen (TOCA) Competitors

Tocagen logo

TOCA vs. ZYME, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, and OSTX

Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and OS Therapies (OSTX).

Tocagen vs. Its Competitors

Tocagen (NASDAQ:TOCA) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Tocagen has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Tocagen has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tocagen$40K6,918.57-$63.52M-$2.69-4.30
Zymeworks$122.87M8.78-$118.67M-$0.97-14.80

Zymeworks has a net margin of -182.75% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -23.00% beat Tocagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Tocagen-176,433.34% -327.74% -111.87%
Zymeworks -182.75%-23.00%-18.04%

21.4% of Tocagen shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 10.9% of Tocagen shares are owned by company insiders. Comparatively, 1.9% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zymeworks has a consensus price target of $21.43, indicating a potential upside of 49.22%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Tocagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tocagen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zymeworks
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

In the previous week, Zymeworks had 17 more articles in the media than Tocagen. MarketBeat recorded 17 mentions for Zymeworks and 0 mentions for Tocagen. Zymeworks' average media sentiment score of 0.37 beat Tocagen's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.

Company Overall Sentiment
Tocagen Neutral
Zymeworks Neutral

Summary

Zymeworks beats Tocagen on 13 of the 17 factors compared between the two stocks.

Get Tocagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TOCA vs. The Competition

MetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$276.74M$852.35M$5.67B$9.82B
Dividend YieldN/A4.84%3.79%4.07%
P/E Ratio-4.881.1930.5825.12
Price / Sales6,918.5726.45460.38114.01
Price / CashN/A19.5637.4059.05
Price / Book25.716.589.096.18
Net Income-$63.52M-$4.98M$3.25B$264.89M

Tocagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TOCA
Tocagen
N/A$11.57
+6.9%
N/A+3,390.3%$276.74M$40K-4.8877
ZYME
Zymeworks
2.4824 of 5 stars
$13.38
+2.7%
$21.43
+60.2%
+36.8%$1.01B$122.87M-8.92460
SBTX
Silverback Therapeutics
N/A$16.66
+1.7%
N/A+6.9%$600.73MN/A-6.8883High Trading Volume
MBX
MBX Biosciences
2.5781 of 5 stars
$13.66
+9.1%
$37.63
+175.4%
N/A$449.92MN/A-2.9536News Coverage
Analyst Forecast
AVTE
Aerovate Therapeutics
N/A$7.40
-1.2%
N/A-89.2%$214.49MN/A-2.4720Gap Up
High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$20.35
-4.1%
N/A-39.8%$191.25MN/A-6.5490News Coverage
Gap Down
High Trading Volume
CYBN
Cybin
2.4511 of 5 stars
$7.53
-1.3%
$85.00
+1,028.8%
N/A$177.63MN/A-1.7250News Coverage
Positive News
BIOA
BioAge Labs
N/A$4.53
+1.1%
N/AN/A$162.40M$3.86M0.00N/ANews Coverage
VIRI
Virios Therapeutics
0.107 of 5 stars
$4.77
-2.5%
$5.00
+4.8%
+2,505.9%$91.86MN/A-17.675
WHWK
Whitehawk Therapeutics
N/A$1.77
+3.5%
N/AN/A$83.42M$25.98M-29.5040
OSTX
OS Therapies
2.4501 of 5 stars
$1.85
+3.7%
$18.00
+875.6%
-41.8%$51.84MN/A-2.15N/ANews Coverage
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:TOCA) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners